Full coverageTop News
All coverage
In battle for Indian anti-obesity market, Eli Lilly’s pre-filled pen on one side, Novo Nordisk’s on other
By Sumi Dutta
Wegovy vs Mounjaro: Eli Lilly to launch full-dose pen device in India as obesity drug race heats up
By Jessica Jani
India approves Eli Lilly’s Mounjaro KwikPen for diabetes and obesity, offering a novel dual-action therapy
By Kavita Bajeli Datt
Eli Lilly’s diabetes and weight-loss drug Mounjaro receives Indian regulatory approval for its KwikPen device
By jyothi datta
Eli Lilly reports strong response for Mounjaro in India amid rising diabetes, obesity rates
By Ruchika Sharma and Kamal Kohli
Eli Lilly Mounjaro Sees Strong Reception in India, Rising Demand Amid Obesity, Diabetes Rates
By Maham Fatima
Eli Lilly’s Mounjaro gets marketing approval for weight-loss and diabetes treatment in India
By Fazal Rahim
GLP-1 Showdown In India: Eli Lilly’s Mounjaro Pen Approved Just Days After Novo’s Wegovy Launch
By Deepti Sri
Lilly to launch Mounjaro pen in India to compete with Novo's weight-loss drug Wegovy
By Rishika Sadam and Anil D'silva
Lilly to launch Mounjaro pen in India to compete with Novo's Wegovy
By Rishika Sadam and Anil D'silva
Eli Lilly Says India Response to Obesity Drug Mounjaro Is 'Positive', Will Focus on Meeting Demand
By Rishika Sadam and Janane Venkatraman